<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2497">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05128656</url>
  </required_header>
  <id_info>
    <org_study_id>APHP201253</org_study_id>
    <secondary_id>2020-A01833-36</secondary_id>
    <nct_id>NCT05128656</nct_id>
  </id_info>
  <brief_title>Immune Response of Asymptomatic EHPAD Employees Infected With COVID-19</brief_title>
  <acronym>SERASYMPTO</acronym>
  <official_title>Kinetic of Humoral Immune Response of Asymptomatic Nursing Homes (EHPAD) Employees Infected With Severe Acute Respiratory Syndrome Coronavirus : a Case Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators performed in April 2020, a screening campaign of asymptomatic staff working&#xD;
      in elderly nursing homes in Paris France (EHPAD), where the virus had been circulating&#xD;
      actively in March and April 2020. Among 241 employees tested in four nursing homes, 32&#xD;
      (13.2%) were asymptomatic carriers of Severe Acute Respiratory Syndrome Coronavirus 2&#xD;
      (SARS-Cov-2).&#xD;
&#xD;
      Few data are available concerning the humoral immune response of asymptomatic carriers, the&#xD;
      elicitation and duration of neutralizing antibodies and the duration of protection.&#xD;
&#xD;
      The purpose of the study is to determine whether these asymptomatic persons develop a humoral&#xD;
      immune response, whether this immune response is durable and whether it is protective against&#xD;
      the risk of reinfection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators performed in April 2020, a screening campaign of asymptomatic staff working&#xD;
      in elderly nursing homes in Paris, France, where the virus had been circulating actively in&#xD;
      March and April 2020. Among 241 employees tested in four nursing homes, 32 (13.2%) were&#xD;
      asymptomatic carriers of SARS-Cov-2.&#xD;
&#xD;
      Few data are available concerning the humoral immune response of asymptomatic carriers, the&#xD;
      elicitation and duration of neutralizing antibodies and the duration of protection.&#xD;
&#xD;
      The main objective of this study is to describe the SARS-Cov-2 asymptomatic employees with&#xD;
      positive immunoglobulin G (igG) serology at month 1-2 post infection.&#xD;
&#xD;
      Secondary objectives are&#xD;
&#xD;
        -  To describe the proportion of asymptomatic persons with SARS-Cov-2 antibodies month 3&#xD;
           and 6 post infection&#xD;
&#xD;
        -  To compare the proportion of persons with SARS-Cov-2 antibodies between asymptomatic and&#xD;
           asymptomatic carriers at M1-2 post infection, M3 and M6 post infection&#xD;
&#xD;
        -  To determine the factors associated with the appearance of antibodies ( viral load, age,&#xD;
           sex, previous history, habitus..)&#xD;
&#xD;
        -  To study the neutralizing capacities and immune-profiling of SARS-Cov-2 antibodies in&#xD;
           vitro&#xD;
&#xD;
        -  To evaluate the occurrence of Coronavirus Disease 2019 (COVID-19) reinfections in&#xD;
           asymptomatic carriers during the second wave.&#xD;
&#xD;
      The design will be a case control study between&#xD;
&#xD;
        -  Cases: SARS-Cov-2 asymptomatic nursing homes employees&#xD;
&#xD;
        -  Controls: cohort of patients with a symptomatic COVID-19, preferably recruited in&#xD;
           nursing homes or in case of difficulties in the virology service of COCHIN Hospital.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2022</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Case control longitudinal study, Interventional minimal risk study</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of positive IgG serology</measure>
    <time_frame>month 1-2 post infection</time_frame>
    <description>positive IgG (Immunoglobulin G) SARS-Cov-2 serology after infection of asymptomatic employees</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of positive IgG serology</measure>
    <time_frame>month 3-6 post infection</time_frame>
    <description>positive IgG (Immunoglobulin G) SARS-Cov-2 serology after infection of asymptomatic employees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of positive immunoglobulin M (IgM) serology</measure>
    <time_frame>month 1-2-3 and 6 post infection</time_frame>
    <description>positive IgM SARS-Cov-2 serology after infection of asymptomatic employees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of neutralizing antibodies</measure>
    <time_frame>month 1-2-3 and 6 post infection</time_frame>
    <description>concentration of neutralizing antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>questionnaire</measure>
    <time_frame>month 1-2-3 and 6 post infection</time_frame>
    <description>Associated factors with the presence of antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>re infection</measure>
    <time_frame>through study completion, an average of 8 months</time_frame>
    <description>of asymptomatic patients with SARS-Cov-2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>SARS-Cov-2 asymptomatic nursing homes employees</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>cohort of patients with a symptomatic COVID-19, preferably recruited in nursing homes or in case of difficulties in the virology service of COCHIN Hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>serology</intervention_name>
    <description>serology at M3 and serology at M6</description>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Common inclusion criteria:&#xD;
&#xD;
               -  Age ≥ 18.&#xD;
&#xD;
               -  Health care employees working in the EHPAD who consulted in the Hotel Dieu&#xD;
                  Hospital&#xD;
&#xD;
               -  Affiliated with a health insurance&#xD;
&#xD;
               -  Informed information and consent&#xD;
&#xD;
          -  Inclusion Criteria for Cases (asymptomatic COVID-19 patients) :&#xD;
&#xD;
               -  Health care workers screened SARS-Cov-2 positive for NASopharyngeal swaths during&#xD;
                  screening campaigns for EHPAD staff.&#xD;
&#xD;
               -  Having carried out a follow-up serology (M1 and M2) within the Hotel Dieu.&#xD;
&#xD;
               -  Having never developed symptoms of COVID-19 or have developed some symptoms&#xD;
                  undetected before screening: fever, transient fatigue, rhinorrhea, symptoms that&#xD;
                  may be mistaken for a common winter cold (no respiratory symptoms or prolonged&#xD;
                  fever)&#xD;
&#xD;
          -  Inclusion criteria for controls (symptomatic COVID-19 patients) :&#xD;
&#xD;
               -  Health care workers tested positive for polymerase chain reaction assay (PCR)&#xD;
                  SARS-Cov-2 during screening campaigns for EHPAD staff at the Hotel Dieu.&#xD;
&#xD;
               -  Having carried out a follow-up serology (M1 and M2) within the Hotel Dieu.&#xD;
&#xD;
        COVID-19 symptoms defined by:&#xD;
&#xD;
          -  At least two major signs of COVID-19 among: &gt; fever, cough, chest tightness, bilateral&#xD;
             pneumonia, anosmia, loss of taste.&#xD;
&#xD;
          -  or a major sign and three minor signs among: headache, severe fatigue, diarrhea,&#xD;
             odynophagia, rhinorrhea, suggestive skin signs.&#xD;
&#xD;
        It is part of the database of the virology department of Cochin Hospital (in case of&#xD;
        failure to recruit health care workers in the EHPADs).&#xD;
&#xD;
        *Exclusion criteria :&#xD;
&#xD;
          -  Refuse to participate or inability to obtain informed consent.&#xD;
&#xD;
          -  under guardianship, curators&#xD;
&#xD;
          -  negative SARS-COV-2 PCR&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique Salmon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique Salmon, MD, PhD</last_name>
    <phone>1 42 34 79 56</phone>
    <phone_ext>+33</phone_ext>
    <email>dominique.salmon@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie BENHAMMANI Godard</last_name>
    <phone>1 58 41 12 11</phone>
    <phone_ext>+33</phone_ext>
    <email>marie.godard@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HOTEL DIEU Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Dominique Salmon</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EHPAD employees</keyword>
  <keyword>COVID-19</keyword>
  <keyword>asymptomatic</keyword>
  <keyword>humoral response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

